Pre-Made Recifercept biosimilar, Recombinant Protein: Recombinant therapeutic protein targeting FGF for drug discovery and mechanism of action (MOA) research

Pre-Made Recifercept biosimilar, Recombinant Protein: Recombinant therapeutic protein targeting FGF is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Achondroplasia is a rare genetic disorder caused by mutations in the Fibroblast Growth Factor receptor 3 (FGFR3). These mutations lead to aberrant increase of inhibitory signaling in proliferating chondrocytes at the growth plate. Recifercept is a soluble recombinant human fibroblast growth factor receptor 3 (FGFR3). Recifercept is a potential treatment for this disease using a decoy approach to sequester FGFR3 ligands subsequently normalizing activation of the mutated FGFR3 receptor. Recifercept binds to FGF isoforms in vitro and in cellular model systems and reduces FGFR3 signaling.